Cytokinetics has announced the publication of two manuscripts describing the results of two previously completed Phase II trials of tirasemtiv, a fast skeletal muscle troponin activator, in people with ALS. The papers are published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. Jeremy Shefner, MD, PhD, Professor and Chair at the Department of Neurology at the Upstate Medical University, State University of New York was lead author on both publications. Dr. Shefner commented that these two trials showed that tirasemtiv “appears to be generally well-tolerated and to impact positively tests of strength, endurance and respiratory function that may be relevant to preserving the functional status of patients with ALS.” Results from these two initial trials will inform the ongoing Phase IIb clinical trial, BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The trial is currently enrolling 680 patients.